Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Account Payables: 2022-2025

Historic Change in Account Payables for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $1.3 million.

  • Entrada Therapeutics' Change in Account Payables rose 516.88% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 249.18%. This contributed to the annual value of $991,000 for FY2024, which is 135.33% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Change in Account Payables stood at $1.3 million, which was up 507.79% from -$321,000 recorded in Q2 2025.
  • Entrada Therapeutics' Change in Account Payables' 5-year high stood at $4.6 million during Q4 2022, with a 5-year trough of -$4.4 million in Q2 2023.
  • In the last 3 years, Entrada Therapeutics' Change in Account Payables had a median value of -$321,000 in 2025 and averaged -$248,727.
  • Its Change in Account Payables has fluctuated over the past 5 years, first plummeted by 384.42% in 2023, then surged by 516.88% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Change in Account Payables stood at $4.6 million in 2022, then crashed by 47.62% to $2.4 million in 2023, then grew by 18.29% to $2.8 million in 2024, then spiked by 516.88% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$321,000 for Q2 2025, and -$1.9 million during Q1 2025.